START WITH THE POWER
AND EXPERIENCE OF TYSABRI

BATTLE  TESTED
BATTLE  TESTED

IN THE FIGHT AGAINST RMS

In the 2-year AFFIRM pivotal trial:

83% of patients taking TYSABRI had no sustained physical disability progression for 12 weeks vs 71% with placebo (primary endpoint: percentage with sustained increase in disability was 17% vs 29%; p<0.001)1,2

View the complete AFFIRM study description.

REAL EXPERIENCES WITH TYSABRI

Stephen Newman, MD, and patient Jennifer discuss evidence from the clinical trial as it relates to their own experiences with TYSABRI.

 

AFFIRM=NAtalizumab Safety and EFFIcacy in Relapsing-Remitting MS.
a190,800 patients as of August 2018.3